4-(4-hexyl-phenyl)-butyric acid | 147427-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-hexyl-phenyl)-butyric acid
• 英文别名: 4-(4-Hexyl-phenyl)-buttersaeure；4-(4-Hexylphenyl)butanoic acid
• CAS: 147427-38-1
• 化学式: C₁₆H₂₄O₂
• 分子量: 248.365
• InChiKey: XBEYVXSOFQKTNE-UHFFFAOYSA-N

物化性质

• 沸点：
  379.6±11.0 °C(predicted)
• 密度：
  0.998±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-hexyl-phenyl)-butyric acid 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochlorite 、 sodium tetrahydroborate 、 三氟化硼乙醚 、 氨 、 碳酸氢钠 、 sulfur 、 溶剂黄146 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 氯仿 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 反应 32.5h， 生成 5-(2-chlorophenyl)-7-[2-(4-n-hexylphenyl)ethyl]-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepin-2-one
  参考文献：
  名称：

  Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

  摘要：

  A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (+/-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.

  DOI：

  10.1016/0223-5234(96)85877-6
• 作为产物：
  描述：

  己基苯 在 二硫化碳 、 三氯化铝 、 alkaline solution 、 锌 作用下， 生成 4-(4-hexyl-phenyl)-butyric acid
  参考文献：
  名称：

  US2130989

  摘要：

  公开号：

文献信息

• US2130989
  申请人：——

  公开号：——

  公开（公告）日：——
• DE720469
  申请人：——

  公开号：——

  公开（公告）日：——
• Fl�ssigkristalle mit aliphatischen Gruppen zwischen Cyclohexanringen - Synthesen von 1,4-Bis-(4-n-alkylcyclohexyl)butanen und 4-[4-4(4-n-Alkylcyclohexyl)butyl]cyclohexylestern
  作者：H.-J. Deutscher、K. M�ller、M. Weber、M. Schmidt、R. Frach

  DOI：10.1002/prac.19923340713

  日期：——

  The synthesis of 1,4-bis-(4-n-alkylcyclohexyl) butanes (1), esters of 4-[-(4-n-alkylcyclohexyl)butyl]cyclohexanols (2) and some analogous aromatic compounds are described. The thermal stability of mesophases of these compounds are in the order of the analogous ethylene-bridged liquid crystals. The reason for this result seems to be the combination of molecular rigidity and conformational flexibility.
• Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system
  作者：Y Kawakami、H Kitani、S Yuasa、M Abe、M Moriwaki、M Kagoshima、M Terasawa、T Tahara

  DOI：10.1016/0223-5234(96)85877-6

  日期：1996.1

  A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (+/-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.